S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NYSE:DGX

Quest Diagnostics Stock Forecast, Price & News

$154.95
+5.43 (+3.63%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$151.53
$156.56
50-Day Range
$140.36
$154.95
52-Week Range
$113.36
$160.56
Volume
1.21 million shs
Average Volume
1.23 million shs
Market Capitalization
$19.01 billion
P/E Ratio
9.31
Dividend Yield
1.66%
Beta
1.02
30 days | 90 days | 365 days | Advanced Chart
Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.


Quest Diagnostics logo

About Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
74834L10
Employees
49,000
Year Founded
1967

Sales & Book Value

Annual Sales
$9.44 billion
Cash Flow
$14.52 per share
Book Value
$52.43 per share

Profitability

Net Income
$1.43 billion
Pretax Margin
25.85%

Debt

Price-To-Earnings

Miscellaneous

Free Float
120,896,000
Market Cap
$19.01 billion
Optionable
Optionable

Company Calendar

Ex-Dividend
10/04/2021
Last Earnings
10/20/2021
Dividend Payable
10/20/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/03/2022

Social Links


MarketRank

Overall MarketRank

2.82 out of 5 stars

Medical Sector

33rd out of 1,391 stocks

Medical Laboratories Industry

1st out of 30 stocks

Analyst Opinion: 2.3Community Rank: 3.5Dividend Strength: 4.2Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -












Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

Is Quest Diagnostics a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last twelve months. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Quest Diagnostics stock.
View analyst ratings for Quest Diagnostics
or view top-rated stocks.

How has Quest Diagnostics' stock price been impacted by COVID-19 (Coronavirus)?

Quest Diagnostics' stock was trading at $99.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DGX stock has increased by 55.4% and is now trading at $154.95.
View which stocks have been most impacted by COVID-19
.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Quest Diagnostics
.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) posted its quarterly earnings results on Wednesday, October, 20th. The medical research company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $2.88 by $1.08. The medical research company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.52 billion. Quest Diagnostics had a net margin of 19.77% and a trailing twelve-month return on equity of 31.20%. The firm's revenue for the quarter was down .6% compared to the same quarter last year. During the same period in the prior year, the company posted $4.31 earnings per share.
View Quest Diagnostics' earnings history
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Wednesday, November 17th. Stockholders of record on Wednesday, January 19th will be given a dividend of $0.62 per share on Wednesday, February 2nd. This represents a $2.48 annualized dividend and a dividend yield of 1.60%. The ex-dividend date is Tuesday, January 18th.
View Quest Diagnostics' dividend history
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics pays an annual dividend of $2.48 per share and currently has a dividend yield of 1.66%. Quest Diagnostics has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Quest Diagnostics is 14.89%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 30.58% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.
View Quest Diagnostics' dividend history.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics announced that its Board of Directors has approved a stock buyback program on Thursday, February 4th 2021, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 6.1% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its shares are undervalued.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of $13.500-$13.900 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.930. The company issued revenue guidance of $10.45 billion-$10.60 billion, compared to the consensus revenue estimate of $10 billion.

What price target have analysts set for DGX?

10 analysts have issued 12-month price objectives for Quest Diagnostics' shares. Their forecasts range from $137.00 to $181.00. On average, they expect Quest Diagnostics' share price to reach $159.50 in the next year. This suggests a possible upside of 2.9% from the stock's current price.
View analysts' price targets for Quest Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the following people:
  • Stephen H. Rusckowski, Chairman, President & Chief Executive Officer
  • Mark J. Guinan, Chief Financial Officer & Executive Vice President
  • Jay G. Wohlgemuth, Chief Medical Officer, Senior VP-R&D, Medical
  • Gabrielle Wolfson, SVP, Chief Information & Digital Officer
  • Timothy U. Sharpe, Vice President-Compliance

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics CEO Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among Quest Diagnostics' employees.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.48%), Victory Capital Management Inc. (2.31%), Davis Selected Advisers (2.24%), American Century Companies Inc. (2.14%), Geode Capital Management LLC (2.06%) and Dimensional Fund Advisors LP (1.76%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski.
View institutional ownership trends for Quest Diagnostics
.

Which institutional investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Morgan Stanley, Massachusetts Financial Services Co. MA, American Century Companies Inc., Two Sigma Advisers LP, Victory Capital Management Inc., Scharf Investments LLC, and Deutsche Bank AG. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Gail R Wilensky, Mark Guinan, Michael E Prevoznik, and Stephen H Rusckowski.
View insider buying and selling activity for Quest Diagnostics
or view top insider-selling stocks.

Which institutional investors are buying Quest Diagnostics stock?

DGX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Goldman Sachs Group Inc., Schroder Investment Management Group, Robeco Institutional Asset Management B.V., O Shaughnessy Asset Management LLC, Skandinaviska Enskilda Banken AB publ , and Citadel Advisors LLC.
View insider buying and selling activity for Quest Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $154.95.

How much money does Quest Diagnostics make?

Quest Diagnostics has a market capitalization of $19.01 billion and generates $9.44 billion in revenue each year. The medical research company earns $1.43 billion in net income (profit) each year or $16.65 on an earnings per share basis.

How many employees does Quest Diagnostics have?

Quest Diagnostics employs 49,000 workers across the globe.

Does Quest Diagnostics have any subsidiaries?

The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).

When was Quest Diagnostics founded?

Quest Diagnostics was founded in 1967.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is www.questdiagnostics.com.

Where are Quest Diagnostics' headquarters?

Quest Diagnostics is headquartered at 500 PLAZA DRIVE, SECAUCUS NJ, 07094.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company can be reached via phone at (973) 520-2700, via email at [email protected], or via fax at 201-462-4169.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.